Stifel Financial Corp Sells 188,627 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Stifel Financial Corp reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 52.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 174,366 shares of the medical research company's stock after selling 188,627 shares during the period. Stifel Financial Corp owned approximately 0.10% of IQVIA worth $34,265,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at $33,000. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA in the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter worth about $44,000. Zions Bancorporation N.A. boosted its holdings in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc lifted its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after buying an additional 93 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of a number of recent analyst reports. Morgan Stanley raised their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Barclays restated an "equal weight" rating and issued a $170.00 price target (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the stock from $260.00 to $160.00 in a research report on Friday. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Stock Up 1.7 %

Shares of NYSE IQV traded up $2.51 during mid-day trading on Tuesday, reaching $152.64. The company had a trading volume of 262,814 shares, compared to its average volume of 1,419,078. The stock has a market capitalization of $26.91 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock's 50 day moving average is $170.67 and its 200-day moving average is $193.00.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.